Trump announces plan to impose tariffs on imported generic drugs
U.S. President Donald Trump has announced plans to impose high tariffs on generic drug manufacturers if they continue importing into the U.S. without establishing domestic production. Through his online platform Truth Social, he stated that tariff exemptions would remain in place for the next two years, followed by 100% tariffs for one year, and finally 200% tariffs. The goal of this policy is to encourage generic drug manufacturers to establish production facilities in the U.S.
Trump emphasized that companies failing to build domestic production facilities within the tariff exemption period would face 'penalties' in the form of very high tariffs. The president stated that this measure aims to protect the American people.
Market and pharmaceutical industry reactions to the new tariff plan
The information has caused a sharp decline in the stock prices of pharmaceutical companies such as Sandoz and Teva. While Israeli Teva has production facilities in the U.S., the Swiss group Sandoz does not own any domestic plants.















